

Date – June 03, 2026

To, <b>BSE Limited (“BSE”),</b> Corporate Relationship Department, 2 <sup>nd</sup> Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400001	To, <b>National Stock Exchange of India Limited (“NSE”),</b> “Exchange Plaza”, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051
<b>BSE Scrip code: 543399</b>	<b>NSE Symbol: TARSONS</b>

**Subject: Intimation under Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”).**

Dear Sir/Madam,

This is in furtherance of the earlier intimation dated February 06, 2026, whereby the Company had informed the Stock Exchanges regarding the approval of the Board of Directors of Tarsons Products Limited (“the Company”) for further equity infusion aggregating to EUR 3,000,000 (Three Million Euros Only) in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., Singapore.

The Company had subsequently informed the Stock Exchanges regarding the completion of the first tranche of EUR 300,000 (Three Hundred Thousand Euros only) and the Company had subscribed to 100 equity shares of Tarsons Life Science Pte. Ltd. at a nominal value of EUR 3,000 per share on April 09, 2026.

In continuation thereof and pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Company has completed the second tranche of equity investment amounting to EUR 552,000 (Five Hundred Fifty-Two Thousand Euros Only) in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., incorporated in Singapore, on June 03, 2026. Pursuant to the aforesaid investment, the Company has subscribed to 184 equity shares of Tarsons Life Science Pte. Ltd. at a nominal value of EUR 3,000 per share.

The proceeds of the above investments shall be utilized by the subsidiary towards repayment of its bank loan in Singapore, payment of interest thereon, and for meeting general corporate purposes, operational requirements, and other financial obligations.

The Company shall continue to keep the Stock Exchanges informed regarding the completion of subsequent tranches of the approved equity investment, as and when such investments are made.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as **Annexure-A**.

This is for your information and records.

Thanking you,

**Yours Faithfully,**  
**For Tarsons Products Limited**

**Santosh Kumar Agarwal**  
**CFO, Company Secretary and Compliance Officer**  
**ICSI Membership No. A44836**

*Encl: As mentioned above*

Annexure-A

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:**

Sr. No.	Particulars	Details
1.	Name of the Target Entity, details in brief such as size, turnover, etc.:	<p>Tarsons Life Science Pte. Ltd. ("Target Entity")</p> <p>Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary of Tarsons Products Limited ("the Company") incorporated in Singapore.</p> <p>The Turnover of the Target Entity for the F.Y. 2025-26 is Nil.</p>
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arm's length":</p>	<p>Tarsons Life Science Pte. Ltd. being a wholly-owned subsidiary is a related party of the Company.</p> <p>The transaction falls within the ambit of a related party transaction and is at arm's length basis.</p> <p>None of the Company's promoter/ promoter group have any interest in the Target Entity other than through their shareholding in the Company.</p> <p>Further, Mr. Aryan Sehgal, Mr. Sanjive Sehgal and Mr. Subramanian Arun Kumar are the directors of the Company and also hold directorships in the Target Entity.</p>
3.	Industry to which the entity being acquired belongs:	<p>Tarsons Life Science Pte. Ltd. is engaged in the Non-Operating Financial Holding Companies.</p> <p>(The Target Entity is a Special Purpose Vehicle)</p>
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	<p>The additional capital infusion by the Company is to fund the needs of the target entity towards quarterly repayment of the loan taken from the Bank in Singapore, interest payable thereon and meeting general corporate purposes and other operational and financial expenses.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not Applicable
6.	Indicative time period for completion of the acquisition:	Completed.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same:	Cash Consideration.
8.	Cost of acquisition and/or the price at which the shares are acquired:	<p>Total consideration for the acquisition of 184 equity shares is EUR 552,000 (Five Hundred Fifty-Two Thousand Euros Only), at a nominal value of EUR 3,000 per share.</p>

9.	Percentage of shareholding / control acquired and / or number of shares acquired:	<p>No change in ownership/percentage of shareholding.</p> <p>Tarsons Life Science Pte. Ltd. will continue to be a wholly-owned subsidiary of Tarsons Products Limited.</p> <p>Number of shares allotted: <b>184 shares</b></p>								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary of Tarsons Products Limited.</p> <p>Date of incorporation: November 10, 2023.</p> <p>Country in which the acquired entity has presence: Singapore</p> <p>The turnover of Tarsons Life Science Pte. Ltd. since incorporation is as under:</p> <table border="1" data-bbox="846 667 1484 898"> <thead> <tr> <th>Financial Year</th> <th>Amount in EUR</th> </tr> </thead> <tbody> <tr> <td>2025-26</td> <td>Nil</td> </tr> <tr> <td>2024-25</td> <td>Nil</td> </tr> <tr> <td>2023-24</td> <td>Nil</td> </tr> </tbody> </table> <p>Any other significant information: Nil</p>	Financial Year	Amount in EUR	2025-26	Nil	2024-25	Nil	2023-24	Nil
Financial Year	Amount in EUR									
2025-26	Nil									
2024-25	Nil									
2023-24	Nil									

**For Tarsons Products Limited**

**Santosh Kumar Agarwal**  
**CFO, Company Secretary and Compliance Officer**  
**ICSI Membership No. A44836**